Results 81 to 90 of about 4,215,496 (299)

Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets

mBio, 2020
The SARS-CoV-2 pandemic continues to spread worldwide, with rapidly increasing numbers of mortalities, placing increasing strain on health care systems.
Su-Jin Park, Kwang-Min Yu, Young-Il Kim, Se-Mi Kim, Eun-Ha Kim, Seong-Gyu Kim, Eun Ji Kim, M. A. Casel, Rare Rollon, Seung-Gyu Jang, Minhyeok Lee, Jae-Hyung Chang, Min-Suk Song, H. Jeong, Younho Choi, Weiqiang Chen, Woo-Jin Shin, Jae U. Jung, Y. Choi   +18 more
semanticscholar   +1 more source

Sophora alopecuroides biflavones glycoside, isolated from Sophora alopecuroides, inhibits the secretion of hepatitis B virus surface antigen through direct interaction with its antigenic loop domain

Virology Journal
Background High levels of circulating hepatitis B surface antigen (HBsAg) contribute to the dysfunction of the host immune response against HBV and the persistence of viral infection.
Ya Wang, Linlin Wang, Ge Yang, Lijun Qiao, Rongmei Gao, Huiqiang Wang, Haiyan Yan, Kun Wang, Shuo Wu, Hua Huang, Yuhuan Li   +10 more
doaj   +1 more source

Facing an Epidemic: An Analysis of HIV/AIDS, Antiretroviral Drug, and International Response to the AIDS Pandemic [PDF]

, 2012
More than 33 million people are living with HIV/AIDS around the globe with 68% of all cases occurring in sub-Saharan Africa. The global prevalence rate is shocking considering that the disease was relatively unknown just 30 years ago.
Tate, Michael
core   +1 more source

Reconstitution of hepatitis B virus (HBV)-specific T cell responses with treatment of human immunodeficiency virus/HBV coinfection [PDF]

, 2003
Liver-related mortality is an increasing problem in human immunodeficiency virus (HIV)/hepatitis B virus (HBV)-coinfected patients receiving highly active antiretroviral therapy (HAART).
Bertoletti, A, Gilson, RJ, Lascar, RM, Lopes, AR, Maini, MK   +4 more
core   +1 more source

Real-world effectiveness and safety of oral Azvudine versus Paxlovid for COVID-19 in patients with kidney disease: a multicenter, retrospective, cohort study

BMC Infectious Diseases
Background Patients with kidney disease (KD) are at high risk of contracting COVID-19 and developing severe disease. There is still a lack of guidance regarding the treatment of COVID-19 in patients with KD.
Benchen Rao, Daming Wang, Mengzhao Yang, Chunyu Zhao, Ming Cheng, Silin Li, Donghua Zhang, Hong Luo, Guowu Qian, Ling Wang, Shixi Zhang, Guotao Li, Guangming Li, Zujiang Yu, Zhigang Ren   +14 more
doaj   +1 more source

Comparative analysis of antiviral efficacy of FDA‐approved drugs against SARS‐CoV‐2 in human lung cells

bioRxiv, 2020
Drug repositioning represents an effective way to control the current COVID-19 pandemic. Previously, we identified 24 FDA-approved drugs which exhibited substantial antiviral effect against SARS-CoV-2 in Vero cells.
Meehyun Ko, Sangeun Jeon, W. Ryu, Seungtaek Kim   +3 more
semanticscholar   +1 more source

Interferon free antiviral treatment of chronic hepatitis C in patients affected by β-thalassemia major [PDF]

, 2017
Chronic hepatitis C (CHC) significantly affects the prognosis of liver disease [1] and health related quality of life (HRQOL) in patients with β-thalassemia major [2, 3].
Biliotti, Elisa, Esvan, Rozenn, Franchi, Cristiana, Palazzo, Donatella, Serani, Marco, Silvestri, Alessandro M., Sorrentino, Francesco, Spaziante, Martina, Taliani, Gloria, Volpicelli, Lorenzo   +9 more
core   +1 more source

Transcriptome Analysis Reveals Gemykibivirus Infection Induces Mitochondrial DNA Release in HEK293T Cells

Viruses
Gemykibivirus, an emerging single-stranded DNA (ssDNA) virus of the recently established genus in the family of Genomoviridae, had been discovered in human blood and cerebrospinal fluid and a variety of other body fluids.
Runbo Yang, Hao Yan, Yifan Wang, Wenqing Yang, Jianru Qin   +4 more
doaj   +1 more source

Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant

New England Journal of Medicine, 2022
E. Takashita, N. Kinoshita, S. Yamayoshi, Yuko Sakai-Tagawa, Seiichiro Fujisaki, Mutsumi Ito, K. Iwatsuki-Horimoto, S. Chiba, P. Halfmann, H. Nagai, M. Saito, E. Adachi, D. Sullivan, A. Pekosz, Shinji Watanabe, K. Maeda, M. Imai, H. Yotsuyanagi, H. Mitsuya, N. Ohmagari, M. Takeda, H. Hasegawa, Y. Kawaoka   +22 more
semanticscholar   +1 more source

Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most? [PDF]

, 2014
Objective: The expense of new therapies for HCV infection may force health systems to prioritise the treatment of certain patient groups over others.
Dillon, John, Goldberg, David, Hutchinson, Sharon J, Innes, Hamish   +3 more
core   +1 more source